oral glp 1 agonist Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes VisualAbstract: Daily Oral GLP-1 Receptor
Description
How the formulation may be evaluated Laboratory evaluation may focus on the formulation's stability, temperature sensitivity, visual characteristics, delivery-device behaviour and compatibility with analytical testing procedures
Nationwide retrospective studies utilizing register data from Sweden and Denmark (20132021) and the UK CPRD (20072020) have revealed consistent findings, indicating that GLP-1 RAs are not associated with an elevated risk of suicidality relative to DPP-4 or SGLT-2 inhibitors [77,78]
Tan B, Pan XH, Chew HSJ, et al
After a year, the people taking tirzepatide were: Nearly twice as likely to lose 5% of their body weight
& Cohen-Solal, M
Treatment of HFpEF beyond the SGLT2-Is: Does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients
